ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2152

Inhibition of Fucose Incorporation Abrogates the Development of Arthritis by Suppressing the Inflammatory Macrophage Development and TNF-α Production

Jun Li1, Hui-Chen Hsu2, PingAr Yang1, Qi Wu1, David M. Spalding3, W. Winn Chatham4, Robert P. Kimberly5, S. Louis Bridges Jr.6 and John D. Mountz7, 1Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 2Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Clinical Immunology and Rheum, University of Alabama at Birmingham, Birmingham, AL, 4University of Alabama at Birmingham, Birmingham, AL, 5Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 6Clinical Immunology & Rheum, University of Alabama at Birmingham, Birmingham, AL, 7Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: glycoproteins, macrophages, Rheumatoid arthritis (RA), treatment and tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Fucosylation, catalyzed by fucosyltransferases (Futs), is an important glycosylation process involved in inflammation, cell death, and differentiation. We have observed an extremely high positive correlation between Tnfα and Fucosyltransferases 1 and 3 (Fut1 and Fut3, p=0.0001) in rheumatoid arthritis (RA) synovial tissues. However, the role of fucosylation in RA has not been extensively studied. The purpose of this study is to determine: (i) expression of Futs in different cell population isolated from human RA synovial fluid; (ii) the effect of a fucosylation inhibitor on RA effector cell differentiation; and (iii) the ability of a fucosylation inhibitor to suppress the development of collagen II-induced arthritis (CIA) in mice.

Methods: Twenty RA subjects were recruited in this study. Real-time PCR was used to determine the expression of Fut1 and Fut3 in FACS sorted cell subsets from fresh RA synovial fluids. Purified human synovial macrophages (MΦs) were cultured with GM-CSF and CD4 T cells were polarized towards Th1 and Th17 cells with and without the presence of 15 mM 6-Deoxy-L-galactose (fucose) or its analog, 2-Deoxy-D-galactose (2-D-gal) which can inhibit the fucosylation process. Cytokines in the supernatant were measured by ELISA. CIA was induced in DBA/1J mice. Fucose or 2-D-Gal (200 mg/kg BW, every 2-3 days) was administered via I.P. initiated on Day 1. FACS, ELISA and histopathology analysis were performed on Day 40.

Results: In FACS sorted cells from fresh human RA synovial fluid, the expression of Fut1 and Fut3 was five-fold higher in M1 inflammatory MΦ (CD68+CD80+) compared to M2 MΦ (CD68+CD80–), with lower expression in  Th1, Th17, total memory and naïve CD4 T cells. In vitro 2-D-gal treatment for 3 days lead to dramatic cell death of purified human MΦ and reduced levels of TNF-α (3800 pg/ml vs 450 pg/ml, p<0.001) in the supernatant. There was, however, no inhibitory effect of 2-D-gal on human Th1 or Th17 differentiation in vitro. In vivo treatment of 2-D-gal in DBA/1J mice immunized with bovine CII abrogates the development of arthritis whereas the same dose of fucose exacerbated it (arthritis scores: control, 9.5±1.7; 2-D-gal, 0.5± 0.3; Fucose, 15.3± 2.2, p<0.01). FACS analysis revealed that the percentages of inflammatory MΦ (CD11b+TNF-α+) in the draining LN were reduced by 2-D-gal but were increased by Fucose (control 1.1±0.23; 2-D-gal, 0.6±0.10; Fucose, 1.5± 0.32, p<0.05). 2-D-gal treatment also resulted in significantly decreased levels of TNF-α (130.1 vs 39.4pg/ml, p<0.05) and anti-CII total IgM and IgG in the serum. Joint histopathology showed a significantly decreased macrophage infiltration, synovial hyperplasia, cartilage damage, and bone erosion in 2-D-gal treated mice. No significant liver and renal toxicity and dysfunction was observed.

Conclusion: Our results show that Futs are highly expressed in inflammatory MΦ and fucosylation is a critical process regulating MΦ differentiation and TNF-α production. Inhibition of fucose incorporation by 2-D-gal significantly impairs inflammatory macrophage development and function, completely blocking development of arthritis without systematic toxicity. Our results suggest that MΦ fucosylation may be a new therapeutic target for RA.


Disclosure:

J. Li,
None;

H. C. Hsu,
None;

P. Yang,
None;

Q. Wu,
None;

D. M. Spalding,
None;

W. W. Chatham,
None;

R. P. Kimberly,
None;

S. L. Bridges Jr.,
None;

J. D. Mountz,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inhibition-of-fucose-incorporation-abrogates-the-development-of-arthritis-by-suppressing-the-inflammatory-macrophage-development-and-tnf-%ce%b1-production/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology